The Neuroimmunology and Multiple Sclerosis market are experiencing significant growth due to increasing research focus, advanced treatment options, and rising incidences of autoimmune neurological disorders. The market encompasses therapies, disease-modifying drugs, and diagnostic tools targeting neuroimmunological conditions, particularly Multiple Sclerosis (MS). Advances in understanding the immune system's role in neurological disorders drive the development of novel treatments, including monoclonal antibodies and immunomodulatory drugs. The global prevalence of MS and the demand for effective therapies contribute to market expansion. Geographically, North America and Europe lead, supported by established healthcare infrastructures. The Asia-Pacific region is emerging as a key market, driven by improving healthcare awareness and diagnostic capabilities. The market is characterized by strategic collaborations, research partnerships, and ongoing clinical trials, reflecting a dynamic landscape with a focus on advancing treatments for neuroimmunological disorders.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
